Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neuroblastoma 1Lymphoma 1Colorectal Neoplasms 1

Interventions

Bevacizumab 119Fluorouracil 91Leucovorin 83Cetuximab 83Oxaliplatin 80pembrolizumab 70Irinotecan 67Nivolumab 46Capecitabine 43Specimen Handling 40regorafenib 30Folfox protocol 29trifluridine tipiracil drug combination 28Magnetic Resonance Spectroscopy 27Biopsy 27Panitumumab 26Standard of Care 25HMPL-013 25IFL protocol 21Gemcitabine 20Blood Specimen Collection 19atezolizumab 18Trifluridine 18Cisplatin 18tislelizumab 17balstilimab 16Colonoscopy 16Carboplatin 16encorafenib 15Paclitaxel 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colorectal Neoplasms × eliglustat × 1 year × Clear all
NCT06558773 2026-02-11

GSL Synthetase Inhibitor Plus Immune Checkpoint Inhibitor and/or Regorafenib in Previously Treated pMMR/MSS CRC.

Chinese PLA General Hospital

Phase 2 Recruiting
120 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡